These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
122 related articles for article (PubMed ID: 36049357)
1. The elevated D-2-hydroxyglutarate level found as a characteristic metabolic change of colon cancer in both in vitro and in vivo models. Atalay EB; Kayali HA Biochem Biophys Res Commun; 2022 Oct; 627():191-199. PubMed ID: 36049357 [TBL] [Abstract][Full Text] [Related]
2. Wild-type IDH1 Knockout Leads to G0/G1 Arrest, Impairs Cancer Cell Proliferation, Altering Glycolysis, and the TCA Cycle in Colon Cancer. Atalay EB; Senturk S; Kayali HA Biochem Genet; 2023 Aug; 61(4):1470-1486. PubMed ID: 36633771 [TBL] [Abstract][Full Text] [Related]
3. Metabolomic comparison between cells over-expressing isocitrate dehydrogenase 1 and 2 mutants and the effects of an inhibitor on the metabolism. Wen H; Cho HR; Yun T; Kim H; Park CK; Lee SH; Choi SH; Park S J Neurochem; 2015 Jan; 132(2):183-93. PubMed ID: 25251602 [TBL] [Abstract][Full Text] [Related]
4. Rapamycin (mTORC1 inhibitor) reduces the production of lactate and 2-hydroxyglutarate oncometabolites in IDH1 mutant fibrosarcoma cells. Hujber Z; Petővári G; Szoboszlai N; Dankó T; Nagy N; Kriston C; Krencz I; Paku S; Ozohanics O; Drahos L; Jeney A; Sebestyén A J Exp Clin Cancer Res; 2017 Jun; 36(1):74. PubMed ID: 28578659 [TBL] [Abstract][Full Text] [Related]
5. TOF-SIMS analysis of an isocitrate dehydrogenase 1 mutation-associated oncometabolite in cancer cells. Park J; Na HK; Shon HK; Son HY; Huh YM; Lee SW; Lee TG Biointerphases; 2018 Jan; 13(3):03B404. PubMed ID: 29382206 [TBL] [Abstract][Full Text] [Related]
6. Cancer-associated isocitrate dehydrogenase 1 (IDH1) R132H mutation and d-2-hydroxyglutarate stimulate glutamine metabolism under hypoxia. Reitman ZJ; Duncan CG; Poteet E; Winters A; Yan LJ; Gooden DM; Spasojevic I; Boros LG; Yang SH; Yan H J Biol Chem; 2014 Aug; 289(34):23318-28. PubMed ID: 24986863 [TBL] [Abstract][Full Text] [Related]
7. Minimally Invasive Detection of IDH1 Mutation With Cell-Free Circulating Tumor DNA and D-2-Hydroxyglutarate, D/L-2-Hydroxyglutarate Ratio in Gliomas. Tuna G; Dal-Bekar NE; Akay A; Rükşen M; İşlekel S; İşlekel GH J Neuropathol Exp Neurol; 2022 Jun; 81(7):502-510. PubMed ID: 35582888 [TBL] [Abstract][Full Text] [Related]
8. In silico gene expression analysis reveals glycolysis and acetate anaplerosis in IDH1 wild-type glioma and lactate and glutamate anaplerosis in IDH1-mutated glioma. Khurshed M; Molenaar RJ; Lenting K; Leenders WP; van Noorden CJF Oncotarget; 2017 Jul; 8(30):49165-49177. PubMed ID: 28467784 [TBL] [Abstract][Full Text] [Related]
15. Lack of evidence for substrate channeling or flux between wildtype and mutant isocitrate dehydrogenase to produce the oncometabolite 2-hydroxyglutarate. Dexter JP; Ward PS; Dasgupta T; Hosios AM; Gunawardena J; Vander Heiden MG J Biol Chem; 2018 Dec; 293(52):20051-20061. PubMed ID: 30381394 [TBL] [Abstract][Full Text] [Related]
16. D-2-Hydroxyglutarate Is Necessary and Sufficient for Isocitrate Dehydrogenase 1 Mutant-Induced Li T; Cox CD; Ozer BH; Nguyen NT; Nguyen HN; Lai TJ; Li S; Liu F; Kornblum HI; Liau LM; Nghiemphu PL; Cloughesy TF; Lai A Mol Cancer Res; 2018 Jun; 16(6):947-960. PubMed ID: 29545476 [TBL] [Abstract][Full Text] [Related]
17. Reductive carboxylation and 2-hydroxyglutarate formation by wild-type IDH2 in breast carcinoma cells. Smolková K; Dvořák A; Zelenka J; Vítek L; Ježek P Int J Biochem Cell Biol; 2015 Aug; 65():125-33. PubMed ID: 26007236 [TBL] [Abstract][Full Text] [Related]
18. The oncometabolite D-2-hydroxyglutarate induced by mutant IDH1 or -2 blocks osteoblast differentiation in vitro and in vivo. Suijker J; Baelde HJ; Roelofs H; Cleton-Jansen AM; Bovée JV Oncotarget; 2015 Jun; 6(17):14832-42. PubMed ID: 26046462 [TBL] [Abstract][Full Text] [Related]
19. Non-invasive detection of 2-hydroxyglutarate and other metabolites in IDH1 mutant glioma patients using magnetic resonance spectroscopy. Pope WB; Prins RM; Albert Thomas M; Nagarajan R; Yen KE; Bittinger MA; Salamon N; Chou AP; Yong WH; Soto H; Wilson N; Driggers E; Jang HG; Su SM; Schenkein DP; Lai A; Cloughesy TF; Kornblum HI; Wu H; Fantin VR; Liau LM J Neurooncol; 2012 Mar; 107(1):197-205. PubMed ID: 22015945 [TBL] [Abstract][Full Text] [Related]
20. Serum 2-hydroxyglutarate production in IDH1- and IDH2-mutated de novo acute myeloid leukemia: a study by the Acute Leukemia French Association group. Janin M; Mylonas E; Saada V; Micol JB; Renneville A; Quivoron C; Koscielny S; Scourzic L; Forget S; Pautas C; Caillot D; Preudhomme C; Dombret H; Berthon C; Barouki R; Rabier D; Auger N; Griscelli F; Chachaty E; Leclercq E; Courtier MH; Bennaceur-Griscelli A; Solary E; Bernard OA; Penard-Lacronique V; Ottolenghi C; de Botton S J Clin Oncol; 2014 Feb; 32(4):297-305. PubMed ID: 24344214 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]